![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » IsoRay’s GammaTile Cleared for Treating Recurrent Brain Neoplasms
IsoRay’s GammaTile Cleared for Treating Recurrent Brain Neoplasms
July 10, 2018
IsoRay it received 510(k) clearance for its GammaTile therapy, a device that treats recurrent brain tumors.
The device uses proprietary Cesium-131 seeds within customizable collagen-based carriers to treat the tumors, delivering a fast-acting therapeutic dose near the tumor bed.
The seeds deliver a dose of intense radiation treatment to tissue while limiting exposure to radiation.
Upcoming Events
-
21Oct